Insulin - Therapeutic use
Research News and Information

Saturday, November 21, 2009

Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.

5 Oct 2009 CONTEXT: National public insurance for drugs is often based on evidence of comparative effectiveness and cost-effectiveness. This study describes how that evidence has been used across 3 jurisdictions (Australia, Canada, and Britain) that have been ... Read more...

Early progression of the autonomic dysfunction observed in pediatric type 1 diabetes mellitus.

3 Oct 2009 To focus on early cardiac and vascular autonomic dysfunction that might complicate type 1 diabetes mellitus in children, we planned an observational, cross-sectional study in a population of 93 young patients, under insulin treatment, subdivided in ... Read more...

Leukocytoclastic vasculitis associated with insulin aspart in a patient with type 2 diabetes.

29 Sep 2009 OBJECTIVE: To report a case of leukocytoclastic vasculitis associated with insulin aspart therapy. CASE SUMMARY: A 56-year-old man was admitted to the Department of Endocrinology because of a poorly controlled Type 2 diabetes. In an attempt to reach ... Read more...

Latest indexed articles for 'Insulin - Therapeutic use'

These are the very latest articles for this heading:

• Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. 5 Oct 2009
• Early progression of the autonomic dysfunction observed in pediatric type 1 diabetes mellitus. 3 Oct 2009
• Leukocytoclastic vasculitis associated with insulin aspart in a patient with type 2 diabetes. 29 Sep 2009
• Therapies for type 2 diabetes and coronary artery disease. 29 Sep 2009
• A multicenter, randomized trial of treatment for mild gestational diabetes. 29 Sep 2009
• Glycaemic control in hospitalised diabetic patients at the University Hospital Basel in 2002 and in 2005. 17 Sep 2009
• Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. 14 Sep 2009
• [Self-monitoring blood glucose in patients with type 2 diabetes. Who should do this, how often, when and under which conditions?] 8 Sep 2009
• [Role of complementary medicine in type 1 diabetes mellitus in two Swiss centres] 7 Sep 2009
• Prevention of sternal wound infections after coronary artery bypass graft surgery with use of insulin drug therapy: a review of the literature. 30 Aug 2009
• The 600-step program for type 1 diabetes self-management in youth: the magnitude of the self-management task. 30 Aug 2009
• Trials review: cardiovascular outcome with intensive glycemic control and implications for patients with type 2 diabetes. 30 Aug 2009
• Transient hyperglycaemia in a prediabetic dog treated with prednisone and cyclosporin A. 30 Aug 2009
• Diabetes: HOME reveals new data on a cornerstone of treatment. 30 Aug 2009
• Therapy: Intensive glucose control in the ICU: is sugar nice? 30 Aug 2009
• Differences in outcome between the NICE-SUGAR and Leuven trials: biological mechanisms of intensive glucose control in critically ill patients. 30 Aug 2009
• Differences in outcome between the NICE-SUGAR and Leuven trials: possible methodological explanations. 30 Aug 2009
• A draft at the back door. 30 Aug 2009
• Effect of insulin on airway responsiveness in patients with type 2 diabetes mellitus: a cohort study. 30 Aug 2009
• Maintenance of normoglycemia, insulin therapy, or feeding: why not all three? 30 Aug 2009

See a longer list of these articles.

Technical information about 'Insulin'

Definition: A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).

Chemical name: Insulin (ox), 8A-L-threonine-10A-L-isoleucine-30B-L-threonine-

Registry Number: 11061-68-0

Descriptor UI: D007328

Alternative terms: Insulin; Insulin, Regular; Regular Insulin; Humulin S; Iletin; Insulin A Chain; Insulin, Globin Zinc; Globin Zinc Insulin; Velosulin; Insulin, Regular, Human; Insulin, Regular, Pork; Novolin; Sodium Insulin; Insulin, Sodium; Type I Insulin; Insulin, Type I; Type II Insulin; Insulin, Type II; Humulin; Insulin, Regular, Beef-Pork;

Related Mesh Headings: Hyperinsulinism; Nonsuppressible Insulin-Like Activity; Proinsulin; Receptor, Insulin;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Hypoglycemic Agents;

Tree Number: D06.472.699.587.740.625; D12.644.548.586.740.625;

Technical Notes: /blood: consider also HYPERINSULINEMIA (excessively high blood insulin levels) but do not confuse with HYPERINSULINISM (excessive secretion of insulin by pancreas); /immunology: consider also INSULIN ANTIBODIES; precursor = PROINSULIN; INSULIN INFUSION SYSTEMS is available